A Risk Sciences International news item posted on April 12, 2022 and last updated on April 12, 2022
Quinolones, are a class of widely used and popular powerful antibiotics with broad coverage. RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski, recently published a series of three papers on investigating the risk of acute liver failure (ALF) following systemic administration of quinolones, based on a synthesis of evidence from available clinical trials, the US FDA Adverse Event Reporting System (FAERS), and a large US database of electronic health records (EHR).
Although clinical trials provided little evidence of an increased risk, there were reports in FAERS of quinolone-linked ALF cases. Although the primary EHR analysis did not reveal an overall association between quinolones as a class and ALF risk, a possible risk was identified among those with no or few comorbidities, those ≤ 60 years of age, women, men, African Americans, and Caucasians.
The authors noted that elevated risks seen in some subgroups warrant further investigation.
More RSI News
Willhite receives prestigious SOT award
Calvin C. Willhite, an Associate Expert with Risk Sciences International working on a range of toxicological risk issues, was just announced as the recipient of the prestigious…
RSI gives keynote
RSI experts Jennifer Go and Daniel Krewski, were recently invited to present a paper on maternal and child environmental heath during a global, virtual workshop originating in Foshan, Guangdong, China.
RSI hosts Mitacs intern
Risk Sciences International will host Abdallah Alami as an intern in statistics with support from the Mitacs Accelerate program. This unique university-industry program supports interns at…
Dr. Mattison chairs NAM report
Compounded medications prepared by pharmacists or physicians have been used extensively throughout history as a mainstay of therapeutics. Over the past half-century – with the…